Using pretreatment quality of life perceptions to predict response to sumatriptan in migraineurs

Headache

Volumn 37, Issue 10, 1997, Pages 630-634

  Litaker, David G ^a   Solomon, Glen D ^a   Genzen, Jonathan R ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Cleveland Clinic Foundation ^*

Author keywords

Decision making; Medical effectiveness; Migraine; Quality of life; Sumatriptan

Indexed keywords

SUMATRIPTAN;

ADULT; ARTICLE; DECISION MAKING; DISEASE ASSOCIATION; DISEASE SEVERITY; FOLLOW UP; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MEDICAL RECORD; MIGRAINE; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REGRESSION ANALYSIS;

ADULT; AGED; FEMALE; FORECASTING; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PERCEPTION; QUALITY OF LIFE; SEROTONIN AGONISTS; SUMATRIPTAN;

EID: 0031434841     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4610.1997.3710630.x     Document Type: Article

References (13)

1. Osterhaus JT, Townsend RJ, Gandek B, Ware JE Jr. Measuring the functional status and well-being of patients with migraine headache. Headache. 1994;34:337-343.
2. Solomon GD. Quality of life assessment in patients with headache. Pharmacoeconomics. 1994;6:34-41.
3. Morris BA, Van Niman SE, Perlin T, et al. Health care professionals' accuracy in predicting patients' preferred code status. J fam Pract. 1995;40:41-44.
4. Dahlof CG, Dimenas E. Migraine patients experience poorer subjective well-being/quality of life even between attacks. Cephalalgia. 1995;15:31-36.
5. Stewart AL, Hays RD, Ware JE Jr. The MOS short-form general health survey. Reliability and validity in a patient population. Med Care. 1988;26:724-735.
6. Litaker DG, Solomon GD, Genzen JR. Impact of sumatriptan on clinic utilization and costs of care in migraineurs. Headache. 1996;36:538-541.
7. Solomon GD, Skobieranda FG, Gragg LA. Does quality of life differ among headache diagnoses? Analysis using the Medical Outcomes Study Instrument. Headache. 1994;34:143-147.
8. Spitzer RL, Kroenke K, Linzer M, et al. Health-related quality of life in primary care patients with mental disorders. Results from the PRIME-MD 1000 Study. JAMA. 1995;274:1511-1517.
9. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40:373-383.
10. Dechant KL, Clissold SP. Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs. 1992;43:776-798.
11. 1995 Red Book Pharmaceutical Pricing Index. 1995;14:32.
12. Sherbourne CD, Wells KB, Meredith LS, Jackson CA, Camp P. Comorbid anxiety disorder and the functioning and well-being of seriously ill patients of general medical providers. Quality Life Res. 1995;4:484.
13. Overmeyer RH. The clinical use of serotonin receptors in migraine, emesis, and other presentations. Mod Med. 1990;58:32-40.